SELUTION SLR PTA Drug-Eluting Balloon in Japan
By Azmed Devices Editorial Team
Cordis has officially launched the SELUTION SLR PTA Drug-Eluting Balloon in Japan to treat peripheral artery disease, following positive results from the SELUTION SFA Japan clinical trial.
According to Cordis, the company has officially launched and made the SELUTION SLR PTA Drug-Eluting Balloon (DEB) available for use in Japan. This device is specifically engineered to administer sirolimus in a controlled, sustained manner, which is intended to reduce restenosis and restore proper vessel function in patients.
The clinical foundation for this launch is the SELUTION SFA Japan clinical trial, which Cordis reports demonstrated durable clinical outcomes within a complex patient population. According to Cordis, study data showed an 81.5% primary patency rate and 93.8% of patients remained free from reintervention through a three-year period. According to Cordis, this marks the first sirolimus-eluting balloon approved in the region for treating peripheral artery disease.
Medical experts involved in the study, including Dr. Yoshimitsu Soga and Dr. Osamu Iida, noted that the device offers sustained efficacy and safety. According to Cordis, Chief Medical Officer Dr. George Adams emphasized that the launch reflects the company's commitment to expanding innovative treatment options for peripheral artery disease. Cordis intends to continue collaborating with the Japanese medical community to enhance patient care and support broader clinical adoption.
Source
This article summarizes an official Cordis announcement. Read the original at https://cordis.com/emea/news/selution-slr-pta-drug-eluting-balloon-in-japan. Product availability in Azerbaijan is subject to local registration; contact Azmed Devices for current status.
